Sipuleucel-T
| Sipuleucel-T | |
|---|---|
| Term | Sipuleucel-T |
| Short definition | sipuleucel-T - (pronounced) (SY-puh-LOO-sel. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
sipuleucel-T - (pronounced) (SY-puh-LOO-sel. . . ) vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is resistant to castration (has not responded to treatments to lower testosterone levels). Sipuleucel-T is made from a patient's immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T can help the immune system kill prostate cancer cells. It is a type of autologous cellular immunotherapy and a type of dendritic cell vaccine. Also called APC 8015 and Provenge
External links
- Medical encyclopedia article on Sipuleucel-T
- Wikipedia's article - Sipuleucel-T
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski